Muresan, Bogdan; Mamolo, Carla; Cappelleri, Joseph C.; Leip, Eric; Viqueira, Andrea; Heeg, Bart published an article in 2021, the title of the article was An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:
Bosutinib, nilotinib and dasatinib are approved for the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). In the absence of head-to-head comparisons between second-generation tyrosine kinase inhibitors (TKIs), the objective of this study was to indirectly compare the efficacy of bosutinib with nilotinib and dasatinib in first-line (1L) CP-CML. Cross-trial heterogeneity in terms of patient baseline characteristics and imatinib dose escalation are difficult to adjust for in network meta-analyses and anchored matching-adjusted indirect treatment comparisons (MAICs). Therefore, an unanchored MAIC was performed using patient level data from bosutinib (BFORE trial) and published aggregated data from nilotinib (ENESTnd) and dasatinib (DASISION) trials. After matching, cytogenetic and mol. responses, and disease progression, after a min. follow-up of 24 mo were compared between nilotinib vs. bosutinb and dasatinib vs. bosutinib. The comparison of nilotinib vs. bosutinib resulted in no statistically significant differences for MMR at and by 24 mo, MR4 by 24 mo, MR4.5 at and by 24 mo, CCyR by 24 mo, and disease progression, however, a decreased odds of MR4 at 24 mo in favor of bosutinib vs. nilotinib was observed The comparison of dasatinib vs. bosutinib by 24 mo resulted in no statistically significant differences for MMR, disease progression, and CCyR, however a decreased odds of MR4.5 in favor of bosutinib vs. dasatinib was observed Overall, in these analyses bosutinib demonstrates equivalent efficacy to nilotinib and dasatinib in the treatment of patients with newly diagnosed CP-CML. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
The Article related to bosutinib nilotinib dasatinib chronic phase myeloid leukemia, chronic myeloid leukemia, bosutinib, dasatinib, first line, nilotinib, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics